JP2021504404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504404A5 JP2021504404A5 JP2020529368A JP2020529368A JP2021504404A5 JP 2021504404 A5 JP2021504404 A5 JP 2021504404A5 JP 2020529368 A JP2020529368 A JP 2020529368A JP 2020529368 A JP2020529368 A JP 2020529368A JP 2021504404 A5 JP2021504404 A5 JP 2021504404A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- ildr2
- ildr2 antibody
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 101001010614 Homo sapiens Immunoglobulin-like domain-containing receptor 2 Proteins 0.000 claims 2
- 102100030712 Immunoglobulin-like domain-containing receptor 2 Human genes 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 1
- 101100072427 Homo sapiens ILDR2 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229940123751 PD-L1 antagonist Drugs 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592913P | 2017-11-30 | 2017-11-30 | |
| US62/592,913 | 2017-11-30 | ||
| PCT/EP2018/082779 WO2019105972A1 (en) | 2017-11-30 | 2018-11-28 | Ildr2 antagonists and combinations thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504404A JP2021504404A (ja) | 2021-02-15 |
| JP2021504404A5 true JP2021504404A5 (https=) | 2022-01-06 |
| JP7350740B2 JP7350740B2 (ja) | 2023-09-26 |
Family
ID=64559680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529368A Active JP7350740B2 (ja) | 2017-11-30 | 2018-11-28 | Ｉｌｄｒ２アンタゴニストおよびその組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11655297B2 (https=) |
| EP (1) | EP3717007B1 (https=) |
| JP (1) | JP7350740B2 (https=) |
| KR (1) | KR20200096223A (https=) |
| CN (1) | CN111655287B (https=) |
| AR (1) | AR113850A1 (https=) |
| AU (1) | AU2018376231A1 (https=) |
| BR (1) | BR112020010767A2 (https=) |
| CA (1) | CA3083675A1 (https=) |
| IL (1) | IL274751B2 (https=) |
| MX (1) | MX2020005483A (https=) |
| PE (1) | PE20200956A1 (https=) |
| RU (1) | RU2020121533A (https=) |
| SG (1) | SG11202003323TA (https=) |
| TW (1) | TW201934119A (https=) |
| WO (1) | WO2019105972A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20212271A1 (es) * | 2019-04-11 | 2021-11-30 | Bayer Ag | Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1 |
| CN111558038B (zh) * | 2020-05-27 | 2022-04-19 | 北京加美康联健康管理集团有限公司 | 一种用于癌症治疗的免疫检查点抑制剂 |
| CN111574626B (zh) * | 2020-05-27 | 2021-12-31 | 斯爱玲 | 一种ildr2抗体、其药物组合物及其用途 |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| AU2021353004A1 (en) | 2020-09-30 | 2023-04-13 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| JP5607530B2 (ja) | 2007-09-04 | 2014-10-15 | コンピュゲン エルティーディー． | ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用 |
| AU2011272941B2 (en) * | 2010-06-30 | 2014-05-29 | Compugen Ltd. | C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| US9428574B2 (en) * | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| US20170233473A1 (en) * | 2014-05-27 | 2017-08-17 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
| CA2848985A1 (en) * | 2012-02-01 | 2013-08-08 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
| US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| KR102677543B1 (ko) | 2015-09-16 | 2024-06-24 | 아블렉시스, 엘엘씨 | 항-cd115 항체 |
-
2018
- 2018-11-28 WO PCT/EP2018/082779 patent/WO2019105972A1/en not_active Ceased
- 2018-11-28 JP JP2020529368A patent/JP7350740B2/ja active Active
- 2018-11-28 CA CA3083675A patent/CA3083675A1/en active Pending
- 2018-11-28 BR BR112020010767-0A patent/BR112020010767A2/pt not_active IP Right Cessation
- 2018-11-28 US US16/766,224 patent/US11655297B2/en active Active
- 2018-11-28 SG SG11202003323TA patent/SG11202003323TA/en unknown
- 2018-11-28 AU AU2018376231A patent/AU2018376231A1/en not_active Abandoned
- 2018-11-28 EP EP18811506.7A patent/EP3717007B1/en active Active
- 2018-11-28 RU RU2020121533A patent/RU2020121533A/ru unknown
- 2018-11-28 AR ARP180103490A patent/AR113850A1/es not_active Application Discontinuation
- 2018-11-28 IL IL274751A patent/IL274751B2/en unknown
- 2018-11-28 PE PE2020000620A patent/PE20200956A1/es unknown
- 2018-11-28 KR KR1020207015214A patent/KR20200096223A/ko not_active Ceased
- 2018-11-28 MX MX2020005483A patent/MX2020005483A/es unknown
- 2018-11-28 CN CN201880077055.9A patent/CN111655287B/zh active Active
- 2018-11-30 TW TW107142979A patent/TW201934119A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504404A5 (https=) | ||
| Yasinjan et al. | Immunotherapy: a promising approach for glioma treatment | |
| US20190224193A1 (en) | Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases | |
| JP2019511222A5 (https=) | ||
| CY1125429T1 (el) | Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης | |
| JP2014515036A5 (https=) | ||
| JP2015532292A5 (https=) | ||
| Fatoba et al. | Immunotherapies in Huntington's disease and α-Synucleinopathies | |
| JP2020500181A5 (https=) | ||
| JP2016515519A5 (https=) | ||
| JP2019508013A5 (https=) | ||
| EP3071230B1 (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
| JP2014502955A5 (https=) | ||
| JP2015534577A5 (https=) | ||
| JP2016502504A5 (https=) | ||
| JP2017523187A5 (https=) | ||
| JP2022509358A5 (https=) | ||
| JP2018502120A5 (https=) | ||
| JP2016530280A5 (https=) | ||
| JP2017079785A5 (https=) | ||
| JP2016515628A5 (https=) | ||
| JP2015534578A5 (https=) | ||
| JP2015534580A5 (https=) | ||
| RU2020121533A (ru) | Антагонисты ildr2 и их комбинации | |
| JP2016523265A5 (https=) |